SymBio Pharmaceuticals Limited (SYMQY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SymBio Pharmaceuticals Limited (SYMQY) trades at $0.56 with AI Score 53/100 (Grade B). SymBio Pharmaceuticals Limited is a Japanese biopharmaceutical company focused on the development and commercialization of oncology and hematology drugs. Market cap: $26.38M, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for SYMQY: SYMQY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SYMQY against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SYMQY: 2/4 perspectives are bearish. Dominant signal: Moon AI bearish.
SymBio Pharmaceuticals Limited (SYMQY) Healthcare & Pipeline Overview
SymBio Pharmaceuticals Limited, based in Japan, specializes in developing and marketing oncology and hematology drugs, including TREAKISYM for various lymphomas and myeloma. The company focuses on addressing unmet medical needs in these therapeutic areas through innovative formulations and clinical trials, operating within the competitive specialty and generic drug market.
What Is the Investment Thesis for SYMQY?
SymBio Pharmaceuticals Limited presents a focused investment opportunity within the specialty oncology and hematology drug market. The company's established product, TREAKISYM, provides a revenue base while ongoing clinical trials for new formulations and treatments, such as SyB L-1101 and SyB C-1101 for HR-MDS, offer potential growth catalysts. Successful trial outcomes and regulatory approvals could significantly expand the company's market reach and revenue streams. However, the company's negative profit margin of -365.3% indicates a need for improved profitability and efficient cost management. The relatively low beta of 0.46 suggests lower volatility compared to the broader market. Investors should closely monitor clinical trial results, regulatory developments, and the company's ability to achieve profitability.
Based on FMP financials and quantitative analysis
SYMQY Key Highlights
- Market capitalization of $0.03 billion, reflecting its position as a small-cap pharmaceutical company.
- Negative P/E ratio of -1.48, indicating current unprofitability.
- Gross margin of 72.4%, suggesting strong pricing power for its marketed product, TREAKISYM.
- Profit margin of -365.3%, highlighting significant operational losses.
- Beta of 0.46, indicating lower volatility compared to the overall market.
Who Are SYMQY's Competitors?
SYMQY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BIOGF Biocartis Group N.V. | $0.66 | -85.33% | $65.41M | 52 |
| EEOIF Elegance Optical International Holdings Limited | $0.07 | +0.00% | $63.38M | 46 |
| EOFBY Ecofibre Limited | $0.84 | +0.00% | $73.67M | 40 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.05M | 64 |
| HRPMF Herantis Pharma Oyj | $3.51 | +0.00% | $59.47M | 44 |
| ALVO Alvotech | $4.44 | +5.21% | $1.39B | 69 |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SYMQY's Key Strengths?
- Established product (TREAKISYM) with existing market presence.
- Pipeline of new drug formulations and therapies in clinical trials.
- Specialized focus on oncology and hematology.
- Strong gross margin (72.4%) indicating pricing power.
What Are SYMQY's Weaknesses?
- Negative profit margin (-365.3%) indicating significant losses.
- Reliance on a single key product (TREAKISYM).
- Limited geographic presence (primarily Japan).
- Small market capitalization, making it vulnerable to market fluctuations.
What Could Drive SYMQY Stock Higher?
- Phase III clinical trial results for SyB L-1101 in HR-MDS expected in 2027-2029.
- Phase II/III clinical trial results for SyB C-1101 in HR-MDS expected in 2028-2030.
- Development and commercialization of new TREAKISYM formulations (SyB L-1701 and SyB L-1702).
- Development of SyB V-1901, an antiviral drug for infectious diseases.
What Are the Key Risks for SYMQY?
- Unsuccessful clinical trial outcomes for SyB L-1101 and SyB C-1101.
- Regulatory hurdles and delays in drug approvals.
- Competition from established pharmaceutical companies.
- Reliance on a single key product (TREAKISYM).
- Currency risk due to fluctuations in the exchange rate between the U.S. dollar and the Japanese yen.
What Are the Growth Opportunities for SYMQY?
- Expansion of TREAKISYM formulations: The development and commercialization of new TREAKISYM formulations, such as SyB L-1701 and SyB L-1702, offer a growth opportunity by improving patient convenience and treatment efficacy. These formulations could capture a larger share of the existing market for TREAKISYM and potentially extend its lifecycle. The market size for improved formulations of existing cancer drugs is substantial, driven by the demand for better patient outcomes and reduced side effects. Timeline: 2026-2028.
- Development of SyB L-1101 for HR-MDS: The Phase III clinical trial for SyB L-1101, an intravenous formulation for the treatment of higher-risk myelodysplastic syndromes (HR-MDS), represents a significant growth opportunity. Successful trial outcomes and regulatory approval could lead to a new revenue stream in a market with unmet medical needs. The HR-MDS market is growing due to increasing incidence and limited treatment options. Timeline: 2027-2029.
- Advancement of SyB C-1101 for HR-MDS: The Phase II/III clinical trial for SyB C-1101, an oral formulation in combination with Azacitidine for HR-MDS, provides another growth avenue. An oral formulation would offer a more convenient treatment option for patients, potentially increasing adherence and improving outcomes. The market for oral cancer therapies is expanding due to patient preference and ease of administration. Timeline: 2028-2030.
- Development of SyB V-1901 for infectious diseases: The development of SyB V-1901, an antiviral drug for the treatment of infectious diseases, diversifies SymBio's pipeline and opens up a new market opportunity. The infectious disease market is substantial and constantly evolving, with a need for new and effective treatments. Successful development and commercialization of SyB V-1901 could significantly expand SymBio's revenue base. Timeline: 2029-2031.
- Geographic expansion beyond Japan: While currently focused on the Japanese market, SymBio could explore opportunities for geographic expansion into other Asian countries or even Western markets. This would require significant investment in regulatory approvals and commercial infrastructure, but could also unlock substantial growth potential. The global market for oncology and hematology drugs is vast, and expanding internationally could significantly increase SymBio's market share. Timeline: 2030+
What Opportunities Does SYMQY Have?
- Successful clinical trial outcomes and regulatory approvals for new therapies.
- Expansion into new geographic markets.
- Partnerships with larger pharmaceutical companies.
- Development of new indications for existing products.
What Threats Does SYMQY Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays in drug approvals.
- Unsuccessful clinical trial outcomes.
- Generic competition for TREAKISYM.
What Are SYMQY's Competitive Advantages?
- Patented drug formulations: SymBio's patented formulations, such as TREAKISYM, provide a degree of exclusivity and protection from generic competition.
- Clinical trial expertise: The company's experience in conducting clinical trials and navigating the regulatory approval process creates a barrier to entry for new competitors.
- Established relationships with healthcare providers: SymBio has built relationships with hospitals, clinics, and physicians in Japan, which provides a competitive advantage in marketing and selling its products.
- Specialized focus on oncology and hematology: SymBio's deep expertise in these therapeutic areas allows it to develop innovative and targeted therapies.
What Does SYMQY Do?
SymBio Pharmaceuticals Limited, founded in 2005 and headquartered in Tokyo, Japan, is a biopharmaceutical company dedicated to the research, development, manufacturing, and marketing of pharmaceutical drugs, primarily in the fields of oncology and hematology. The company's flagship product is TREAKISYM SyB L-0501, an anti-cancer agent approved and marketed in Japan for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia. SymBio is also actively involved in developing new formulations of TREAKISYM, such as SyB L-1701 (ready-to-dilute) and SyB L-1702 (rapid infusion liquid formulation), to improve patient convenience and treatment efficacy. Furthermore, SymBio is advancing its pipeline with SyB L-1101, an intravenous formulation in Phase III clinical trials for higher-risk myelodysplastic syndromes (HR-MDS), and SyB C-1101, an oral formulation in Phase II/III clinical trials in combination with Azacitidine for HR-MDS. Beyond oncology and hematology, SymBio is exploring antiviral therapies with SyB V-1901 for infectious diseases, demonstrating its commitment to addressing a broader range of medical needs. The company operates primarily in the Japanese market, focusing on bringing innovative and improved treatment options to patients with cancer and other serious illnesses.
What Products and Services Does SYMQY Offer?
- Develops and markets pharmaceutical drugs in oncology and hematology.
- Markets TREAKISYM SyB L-0501 for non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia.
- Develops new formulations of TREAKISYM, including ready-to-dilute and rapid infusion options.
- Conducts Phase III clinical trials for SyB L-1101 to treat higher-risk myelodysplastic syndromes (HR-MDS).
- Conducts Phase II/III clinical trials for SyB C-1101 in combination with Azacitidine to treat HR-MDS.
- Develops SyB V-1901, an antiviral drug for the treatment of infectious diseases.
How Does SYMQY Make Money?
- Develops and patents novel drug formulations and therapies.
- Conducts clinical trials to demonstrate safety and efficacy.
- Obtains regulatory approvals from health authorities in Japan.
- Manufactures and markets pharmaceutical products, primarily TREAKISYM.
- Generates revenue through the sale of its pharmaceutical products.
What Industry Does SYMQY Operate In?
SymBio Pharmaceuticals Limited operates in the competitive specialty and generic drug market, specifically focusing on oncology and hematology. This sector is characterized by high research and development costs, stringent regulatory requirements, and intense competition from both established pharmaceutical giants and smaller biotech companies. The global oncology drug market is projected to reach significant growth in the coming years, driven by an aging population and increasing cancer incidence. SymBio's success depends on its ability to innovate, secure regulatory approvals, and effectively commercialize its products in the Japanese market and potentially beyond.
Who Are SYMQY's Key Customers?
- Hospitals and clinics that treat patients with cancer and hematological disorders.
- Oncologists and hematologists who prescribe TREAKISYM and other SymBio products.
- Patients suffering from non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and HR-MDS.
- Pharmacies that dispense SymBio's medications.
SYMQY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating positive expectations among leadership.
- Community sentiment has turned bullish as new drug developments show promise, generating excitement among investors.
- Analysts are optimistic about the potential market for SymBio's innovative therapies, reinforcing positive perceptions.
- The company's strategic partnerships have strengthened its position in the pharmaceutical landscape, attracting attention from investors.
Bear Case
- Concerns about regulatory hurdles for new drug approvals have surfaced, creating uncertainty in the market's outlook.
- Social sentiment has seen a rise in skepticism regarding the sustainability of recent gains, prompting caution among investors.
- Increased competition in the pharmaceutical sector could challenge SymBio's market share, raising red flags for some traders.
- Recent earnings reports have not met market expectations, leading to a bearish outlook from certain community members.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SYMQY Latest News
No recent news available for SYMQY.
SYMQY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SYMQY.
Price Targets
Wall Street price target analysis for SYMQY.
SYMQY MoonshotScore
What does this score mean?
The MoonshotScore rates SYMQY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Fuminori Yoshida
Unknown
Information on Fuminori Yoshida's background is not available in the provided data. Therefore, his career history, education, and previous roles are Unknown. Further research would be needed to provide a comprehensive profile.
Track Record: Information on Fuminori Yoshida's track record is not available in the provided data. Key achievements, strategic decisions, and company milestones under his leadership are Unknown. Further research would be needed to assess his performance.
SymBio Pharmaceuticals Limited ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. SYMQY is an ADR that allows U.S. investors to invest in SymBio Pharmaceuticals Limited without directly trading on the Tokyo Stock Exchange. Each SYMQY ADR represents a specific number of SymBio Pharmaceuticals Limited's shares traded in its home market.
- Home Market Ticker: Tokyo Stock Exchange, Japan
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: SYMQ
SYMQY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for less transparency and regulatory oversight compared to exchange-listed companies. This tier is distinct from higher OTC tiers like OTCQX and OTCQB, which have more stringent listing standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for low trading volume and liquidity.
- Higher price volatility compared to exchange-listed stocks.
- Risk of fraud or manipulation due to less regulatory oversight.
- Difficulty in obtaining reliable information about the company.
- Verify the company's registration and legal status.
- Assess the availability and reliability of financial information.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's financial condition and prospects.
- Review any available news articles or reports about the company.
- Consult with a financial advisor before investing.
- The company has been in operation since 2005.
- The company has an established product (TREAKISYM) on the market.
- The company is conducting clinical trials for new therapies.
- The company is based in Japan, a country with a well-developed regulatory system.
What Investors Ask About SymBio Pharmaceuticals Limited (SYMQY) — Healthcare
What does SymBio Pharmaceuticals Limited do?
SymBio Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of drugs in the areas of oncology and hematology. Its primary product, TREAKISYM, is used to treat non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia. The company is also developing new formulations of TREAKISYM and conducting clinical trials for new therapies targeting higher-risk myelodysplastic syndromes (HR-MDS) and infectious diseases. SymBio operates primarily in the Japanese market, aiming to address unmet medical needs through innovative pharmaceutical solutions.
What are the main risks for SYMQY?
The main risks for SymBio Pharmaceuticals Limited include the potential for unsuccessful clinical trial outcomes for its pipeline drugs, regulatory hurdles and delays in obtaining drug approvals, and intense competition from established pharmaceutical companies. The company's reliance on a single key product, TREAKISYM, also poses a risk, as does its limited geographic presence primarily in Japan. Additionally, as an ADR, SYMQY is subject to currency risk due to fluctuations in the exchange rate between the U.S. dollar and the Japanese yen, which could impact the value of the investment.
What are the key factors to evaluate for SYMQY?
SymBio Pharmaceuticals Limited (SYMQY) holds an AI score of 53/100 (moderate). Not financial advice.
How frequently does SYMQY data refresh on this page?
SYMQY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SYMQY's recent stock price performance?
SymBio Pharmaceuticals Limited (SYMQY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established product (TREAKISYM) with existing market presence. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SYMQY overvalued or undervalued right now?
Valuing SymBio Pharmaceuticals Limited (SYMQY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SYMQY?
Before investing in SymBio Pharmaceuticals Limited (SYMQY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SYMQY to a portfolio?
Key strength of SymBio Pharmaceuticals Limited (SYMQY): Established product (TREAKISYM) with existing market presence. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- AI analysis is pending, which may provide further insights.
- OTC market stocks carry higher risks than exchange-listed stocks.